One-Liner
A care coordination platform for state newborn screening labs to identify and fast-track infants eligible for new gene therapies like Otarmeni (OTOF gene therapy for deafness).
AI Thinking Process
FDA accelerated approval 23 April 2026 for Otarmeni (Regeneron, OTOF gene therapy for hearing loss). ~12,000 babies/year fail US initial hearing screen; ~500-1,500 OTOF-eligible per year.
Direction skipped. TAM is structurally tiny: 500-1,500 patients/year. At this volume, the gene therapy manufacturer's own patient-services team is the right form. Not enough surface for external SaaS. Same logic for Vertex povetacicept (IgA nephropathy, ~50K US patients).
Kill Reason
Thin TAM: approximately 500-1,500 OTOF-eligible newborns per year in the US. At this patient volume, the gene therapy manufacturer's own patient-services team is the appropriate organizational form — not a third-party SaaS platform. The thin-TAM logic applies even on the patient side.
Risk Analysis
Risk analysis available for latest engine ideas.
Loading...
Related ideas you can explore free:
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.
killed: 5+ funded competitors including Cast AI ($1B valuation), OneChronos (backed by Nobel laureate), Akash Network (decentralized, 80% cheaper), Argentum AI (blockchain-settled). Market is claimed with massive capital.
killed: Template epidemic (G003) + industry-pain-form death pattern (G005) fire simultaneously. 13+ existing compliance tools. A prompt could do 80% of this.